These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 20506355)

  • 1. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.
    Seibold JR; Denton CP; Furst DE; Guillevin L; Rubin LJ; Wells A; Matucci Cerinic M; Riemekasten G; Emery P; Chadha-Boreham H; Charef P; Roux S; Black CM
    Arthritis Rheum; 2010 Jul; 62(7):2101-8. PubMed ID: 20506355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
    Furuya Y; Kuwana M
    J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.
    King TE; Behr J; Brown KK; du Bois RM; Lancaster L; de Andrade JA; Stähler G; Leconte I; Roux S; Raghu G
    Am J Respir Crit Care Med; 2008 Jan; 177(1):75-81. PubMed ID: 17901413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
    Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S
    Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
    Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
    Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
    Galiè N; Beghetti M; Gatzoulis MA; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
    Circulation; 2006 Jul; 114(1):48-54. PubMed ID: 16801459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP; Humbert M; Rubin L; Black CM
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.
    King TE; Brown KK; Raghu G; du Bois RM; Lynch DA; Martinez F; Valeyre D; Leconte I; Morganti A; Roux S; Behr J
    Am J Respir Crit Care Med; 2011 Jul; 184(1):92-9. PubMed ID: 21474646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
    Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
    Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
    Korn JH; Mayes M; Matucci Cerinic M; Rainisio M; Pope J; Hachulla E; Rich E; Carpentier P; Molitor J; Seibold JR; Hsu V; Guillevin L; Chatterjee S; Peter HH; Coppock J; Herrick A; Merkel PA; Simms R; Denton CP; Furst D; Nguyen N; Gaitonde M; Black C
    Arthritis Rheum; 2004 Dec; 50(12):3985-93. PubMed ID: 15593188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.
    Volkmann ER; Tashkin DP; Roth MD; Clements PJ; Khanna D; Furst DE; Mayes M; Charles J; Tseng CH; Elashoff RM; Assassi S
    Arthritis Res Ther; 2016 Dec; 18(1):305. PubMed ID: 28038680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
    Ahmadi-Simab K; Hellmich B; Gross WL
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bosentan in systemic sclerosis.
    Heresi GA; Minai OA
    Drugs Today (Barc); 2008 Jun; 44(6):415-28. PubMed ID: 18596996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung disease.
    Mittoo S; Jacob T; Craig A; Bshouty Z
    Can Respir J; 2010; 17(6):282-6. PubMed ID: 21165350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis.
    Sfikakis PP; Papamichael C; Stamatelopoulos KS; Tousoulis D; Fragiadaki KG; Katsichti P; Stefanadis C; Mavrikakis M
    Arthritis Rheum; 2007 Jun; 56(6):1985-93. PubMed ID: 17530638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bosentan in pulmonary arterial hypertension secondary to scleroderma.
    Joglekar A; Tsai FS; McCloskey DA; Wilson JE; Seibold JR; Riley DJ
    J Rheumatol; 2006 Jan; 33(1):61-8. PubMed ID: 16395751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.